Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 24259625)

1.

Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.

Venci JV, Gandhi MA.

Ann Pharmacother. 2013 Dec;47(12):1697-702. doi: 10.1177/1060028013509232. Epub 2013 Oct 23. Review. Erratum in: Ann Pharmacother. 2014 May;48(5):668. Dosage error in article text.

PMID:
24259625
2.

Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.

Burness CB, Deeks ED.

CNS Drugs. 2014 Apr;28(4):373-87. doi: 10.1007/s40263-014-0155-5. Review.

PMID:
24623127
3.

Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.

Linker RA, Gold R.

Curr Neurol Neurosci Rep. 2013 Nov;13(11):394. doi: 10.1007/s11910-013-0394-8. Review.

PMID:
24061646
4.

[Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].

Matolcsi J, Rózsa C.

Ideggyogy Sz. 2015 Jan 30;68(1-2):7-14. Review. Hungarian.

PMID:
25842911
5.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673.

6.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

7.

Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.

Stangel M, Linker RA.

Expert Rev Clin Pharmacol. 2013 Jul;6(4):355-62. doi: 10.1586/17512433.2013.811826. Review.

PMID:
23927662
8.

Dimethyl fumarate (Tecfidera) for multiple sclerosis.

[No authors listed]

Med Lett Drugs Ther. 2013 Jun 10;55(1418):45-7. No abstract available.

PMID:
24662841
10.

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.

Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT.

Mult Scler. 2014 Feb;20(2):243-52. doi: 10.1177/1352458513507817. Epub 2013 Oct 22.

PMID:
24150779
11.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.

Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26. Review.

PMID:
24195574
12.

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators.

Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Erratum in: Lancet. 2009 Apr 18;373(9672):1340.

PMID:
18970976
13.

Dimethyl fumarate for relapsing-remitting multiple sclerosis.

[No authors listed]

Drug Ther Bull. 2014 Sep;52(9):105-8. doi: 10.1136/dtb.2014.9.0279.

PMID:
25213591
14.

Dimethyl fumarate (Tecfidera) for multiple sclerosis.

Robinson A.

Nurse Pract. 2014 Jul 13;39(7):10-1. doi: 10.1097/01.NPR.0000450384.22603.87. No abstract available.

PMID:
24932788
15.

The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.

Kawalec P, Mikrut A, Wiśniewska N, Pilc A.

Curr Neuropharmacol. 2014 May;12(3):256-68. doi: 10.2174/1570159X12666140115214801.

16.

Dimethyl fumarate : a Janus-faced substance?

Kees F.

Expert Opin Pharmacother. 2013 Aug;14(11):1559-67. doi: 10.1517/14656566.2013.804912. Epub 2013 May 22. Review.

PMID:
23697607
17.

Dimethyl fumarate for multiple sclerosis.

Papadopoulou A, D'Souza M, Kappos L, Yaldizli O.

Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12. doi: 10.1517/13543784.2010.534778. Epub 2010 Nov 11. Review.

PMID:
21067468
18.

Response to comment on "Dimethyl fumarate (tecfidera): a new oral agent for multiple sclerosis".

Venci J, Gandhi MA.

Ann Pharmacother. 2014 Nov;48(11):1537. doi: 10.1177/1060028014546739. No abstract available.

PMID:
25301830
19.

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.

Kita M, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Sarda SP, Agarwal S, Kong J, Zhang A, Viglietta V, Sheikh SI, Seidman E, Dawson KT.

Mult Scler. 2014 Feb;20(2):253-7. doi: 10.1177/1352458513507818. Epub 2013 Oct 22.

PMID:
24150778
20.

Recognizing and overcoming potential barriers to oral medications for MS.

Moses H Jr.

J Clin Psychiatry. 2014 Oct;75(10):e28. doi: 10.4088/JCP.13037nr3c.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk